UNSPSC 51282522: Cefalexin hydrochloride

This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O4S.CLH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6VJE5G3D98. European Medicines Agency schedules cefalexin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01097MIG. The term cefalexin hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cefalexin hydrochloride under HS 29419000.

SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)SC1)C(=O)O.O.CL.

UNSPSC 51282522 Cefalexin hydrochloride is a Commodity code nominally describing a specific antibiotic pharmaceutical, but recent state and local procurement activity under this code shows little alignment with the code's stated scope. The opportunities posted against this code span unrelated pharmaceutical and medical supply categories—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical consumables (electrodes, endotracheal tubes, airway devices, bandages), and multi-source generic pharmaceuticals and OTC products. The mismatch suggests either systematic tagging misclassification or that procurement offices are using broad pharmaceutical commodity codes as catch-all categories for diverse health-related supply and service acquisitions. State and local governments appear to be buying pharmaceutical products, medical emergency supplies, and pharmacy benefit administration services under codes nominally tied to specific drug formulations, with issuing bodies spanning county health departments, city fire departments, state HHS commissions, and multistate cooperative purchasing alliances.

The geographic spread includes Florida (Seminole County), Texas (Texas Health and Human Services Commission), and Minnesota (MMCAP, serving participating state and local governments including Oregon), with activity extending across the Midwest and Southeast. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026, due July 26, 2023); the City of Tampa's ITB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated value of $700,000.00 and SLBE sheltered-market designation (posted March 25, 2026, due March 13, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products to be awarded by March 26, 2026, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission also posted an RFI on direct-to-manufacturer prescription programs (April 3, 2026) signaling state-level interest in pharmacy benefit innovation. Given the code's nominal specificity and the breadth of products actually being solicited, vendors should verify code alignment before pursuing opportunities tagged under this Commodity code.